糖尿病腎臟病市場規模、佔有率和成長分析：按藥物類別、疾病階段、糖尿病類型、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球糖尿病腎病變市場價值為 32 億美元，預計到 2025 年將成長至 33.7 億美元，到 2033 年將成長至 51.4 億美元，在預測期（2026-2033 年）內複合年成長率為 5.4%。

全球糖尿病腎病變市場的主要驅動力是糖尿病盛行率的上升和老化，導致慢性腎臟併發症患者數量不斷增加，需要接受各種治療。該市場涵蓋篩檢工具、生物標記、藥物和透析技術，旨在應對高發病率、頻繁住院和醫療成本飆升等挑戰。 SGLT2抑制劑在臨床試驗中展現的腎臟保護作用，正推動治療策略向預防措施和個人化治療的重大轉變。此外，腎臟病學和糖尿病交叉領域的技術進步，例如改進的生物標記、數位化血糖值監測和遠端醫療，正在促進腎臟損傷的早期發現和管理，從而影響治療路徑並降低住院成本。人工智慧的整合正在增強早期診斷能力，實現更準確的風險評估，並為新興地區和居家照護領域創造創新投資機會。

全球糖尿病腎病變市場按藥物類別、疾病階段、糖尿病類型、給藥途徑、分銷管道、最終用戶和地區進行細分。依藥物類別分類，市場分為SGLT2抑制劑、ACE抑制劑、血管收縮素II受體阻斷劑（ARB）、鹽皮質激素受體拮抗劑（MRA）、GLP-1受體促效劑、內皮素受體拮抗劑、腎素抑制劑、聯合治療和其他藥物。依疾病階段分類，市場分為「早期糖尿病腎臟病」、「中期糖尿病腎臟病」、「晚期糖尿病腎臟病」及「糖尿病相關末期腎功能衰竭（ESRD）」。依糖尿病類型分類，市場分為「第1型糖尿病相關腎臟病」及「第2型糖尿病相關腎臟病」。根據給藥途徑，市場分為口服、注射和靜脈注射。根據分銷管道，市場分為醫院藥房、零售藥房和線上藥房。根據最終用戶，數據分為醫院、腎臟專科診所、門診診所和居家照護機構。根據地區，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球糖尿病腎病變市場成長要素

全球糖尿病盛行率的上升導致糖尿病腎病變高風險族群數量顯著增加，進而引發了對有效診斷、持續監測和治療方案日益成長的需求。隨著患者群體的擴大，醫療專業人員越來越重視早期發現和長期管理策略。這種日益增強的意識正在推動藥物研發、生物標記研究和創新醫療服務模式的投資。為此，製藥公司和醫療設備製造商正在拓展產品線並努力獲得監管部門的批准。同時，保險公司和政策制定者也更嚴格地審查資源分配，透過加強臨床參與和活性化商業活動，促進整體市場成長。

全球糖尿病腎臟病市場面臨的限制因素

糖尿病腎臟病治療方法的研發、生產和分銷成本高昂，會嚴重阻礙市場成長。隨著患者治療費用的承受能力下降，以及醫療保健預算日益緊張，獲得保險報銷變得越來越困難，限制了藥物在臨床實踐中的廣泛應用。因此，不斷增加的支出迫使企業採取謹慎或高價的定價策略，這可能會延遲藥物被納入健保報銷範圍，並限制病患的用藥機會，尤其是在資源匱乏的地區。此外，這種情況也會導致市場分割，使一些製造商在某些地區猶豫是否要推出產品。最終，這些因素會減緩配套診斷和上市後支持的發展勢頭，進一步阻礙合格的患者及時獲得創新治療方法。

糖尿病腎病變全球市場趨勢

全球糖尿病腎病變市場正經歷著向精準醫療的顯著轉變，其特徵是生物標記識別能力的提升和個人化治療策略的發展。這一趨勢正在加速建立個人化治療路徑，從而提高患者參與度和風險分層。專科診所與診斷技術創新者之間的合作正在加速個人化護理方案的實施，而保險公司也日益推行基於價值的策略來支持精準醫療干預。這種不斷變化的格局正在推動標靶臨床開發，促進跨學科研究，使個人化治療成為長期疾病管理的基石，並將治療結果與醫療團隊的目標一致，最終實現以患者為中心的優質醫療服務。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球糖尿病腎臟病市場規模：依藥物類別分類

• SGLT2抑制劑
• ACE抑制劑
• 血管收縮素II受體阻斷劑（ARB）
• 鹽皮質激素受體拮抗劑（MRA）
• GLP-1受體促效劑
• 內皮素受體拮抗劑
• 腎素抑制劑
• 聯合治療
• 其他

全球糖尿病腎臟病市場規模：依疾病進展階段分類

• 早期糖尿病腎臟病
• 中度糖尿病腎臟病
• 進行性糖尿病腎臟病
• 與糖尿病相關的末期腎功能衰竭（ESRD）

全球糖尿病腎臟病市場規模：依糖尿病類型分類

• 與第1型糖尿病相關的腎臟疾病
• 與第2型糖尿病相關的腎臟疾病

全球糖尿病腎臟病市場規模：依給藥途徑分類

• 口服
• 注射藥物
• 靜脈

全球糖尿病腎臟病市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球糖尿病腎臟病市場規模：依最終用戶分類

• 醫院
• 腎臟專科診所
• 門診部
• 居家醫療

全球糖尿病腎臟病市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• AstraZeneca
• Boehringer Ingelheim
• Eli Lilly and Company
• Novo Nordisk
• Johnson & Johnson Innovative Medicine
• Bayer AG
• Merck & Co., Inc.
• Pfizer Inc.
• AbbVie Inc.
• Sanofi
• Novartis AG
• GSK plc
• Mitsubishi Tanabe Pharma Corporation
• TheracosBio
• Lexicon Pharmaceuticals
• Otsuka Pharmaceutical Co., Ltd.
• Daewoong Pharmaceutical Co., Ltd.
• GC Biopharma
• Glenmark Pharmaceuticals Ltd.
• Taisho Pharmaceutical Co., Ltd.

結論與建議

Global Diabetic Kidney Disease Market size was valued at USD 3.2 Billion in 2024 and is poised to grow from USD 3.37 Billion in 2025 to USD 5.14 Billion by 2033, growing at a CAGR of 5.4% during the forecast period (2026-2033).

The global diabetic kidney disease market is largely driven by the increasing prevalence of diabetes and aging populations, leading to a rise in patients with chronic kidney complications requiring various interventions. This market encompasses screening tools, biomarkers, pharmaceuticals, and dialysis technologies, addressing significant morbidity, frequent hospital admissions, and escalating healthcare costs. A shift towards preventive measures and tailored therapies is evident, supported by successful trials of SGLT2 inhibitors that demonstrate renal protection. Additionally, advancements in technology bridging nephrology and diabetology-such as improved biomarkers, digital glucose tracking, and telemedicine-facilitate earlier detection and management of renal injuries, thus impacting treatment pathways and reducing hospitalization costs. The integration of AI enhances early diagnosis, enabling more precise risk assessments and fostering innovative investment opportunities in emerging regions and home-based care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Kidney Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetic Kidney Disease Market Segments Analysis

The global diabetic kidney disease market is segmented by drug class, disease stage, diabetes type, route of administration, distribution channel, end user and region. Based on drug class, the market is segmented into SGLT2 Inhibitors, ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Mineralocorticoid Receptor Antagonists (MRAs), GLP-1 Receptor Agonists, Endothelin Receptor Antagonists, Renin Inhibitors, Combination Therapies and Others. Based on disease stage, the market is segmented into Early-Stage Diabetic Kidney Disease, Moderate Diabetic Kidney Disease, Advanced Diabetic Kidney Disease and End-Stage Renal Disease (ESRD) Associated with Diabetes. Based on diabetes type, the market is segmented into Type 1 Diabetes-Associated Kidney Disease and Type 2 Diabetes-Associated Kidney Disease. Based on route of administration, the market is segmented into Oral, Injectable and Intravenous. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Kidney Clinics, Ambulatory Care Centers and Home Care Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetic Kidney Disease Market

The global increase in diabetes prevalence significantly raises the number of individuals susceptible to diabetic kidney disease, thereby escalating the demand for effective diagnosis, continuous monitoring, and treatment solutions. Healthcare professionals emphasize the importance of early identification and long-term management strategies due to the rising patient population. This growing awareness stimulates investment in drug development, biomarker research, and innovative care delivery models. In response, pharmaceutical companies and medical device manufacturers expand their product lines and pursue regulatory approvals. Concurrently, payers and policymakers are reviewing resource allocation more rigorously, collectively contributing to market growth through enhanced clinical engagement and increased commercial activity.

Restraints in the Global Diabetic Kidney Disease Market

The substantial costs associated with the development, production, and distribution of therapies for diabetic kidney disease can significantly hinder market growth. As affordability declines and payer budgets become strained, securing reimbursement becomes increasingly challenging, limiting widespread clinical adoption. Consequently, elevated spending prompts companies to adopt cautious or premium pricing strategies, which can delay their inclusion in formularies and restrict patient access, particularly in resource-limited areas. Additionally, this scenario can fragment the market into smaller segments, causing some manufacturers to hesitate in their regional launches. Ultimately, this landscape dampens the momentum for complementary diagnostics and post-marketing support, further impeding the timely availability of innovations to eligible patients.

Market Trends of the Global Diabetic Kidney Disease Market

The global market for diabetic kidney disease is witnessing a significant shift towards precision medicine, characterized by enhanced biomarker identification and the development of personalized therapeutic strategies. This trend facilitates the creation of tailored treatment pathways that improve patient engagement and risk stratification. The collaboration between specialty clinics and diagnostic innovators accelerates the adoption of individualized care plans, while payers increasingly pursue value-based approaches to support precision interventions. This evolving landscape promotes targeted clinical development and encourages cross-disciplinary research, making personalized therapies pivotal for long-term disease management and aligning outcomes with the objectives of care teams, ultimately enhancing patient-centric care.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Diabetic Kidney Disease Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• SGLT2 Inhibitors
• ACE Inhibitors
• Angiotensin II Receptor Blockers (ARBs)
• Mineralocorticoid Receptor Antagonists (MRAs)
• GLP-1 Receptor Agonists
• Endothelin Receptor Antagonists
• Renin Inhibitors
• Combination Therapies
• Others

Global Diabetic Kidney Disease Market Size by Disease Stage & CAGR (2026-2033)

• Market Overview
• Early-Stage Diabetic Kidney Disease
• Moderate Diabetic Kidney Disease
• Advanced Diabetic Kidney Disease
• End-Stage Renal Disease (ESRD) Associated with Diabetes

Global Diabetic Kidney Disease Market Size by Diabetes Type & CAGR (2026-2033)

• Market Overview
• Type 1 Diabetes-Associated Kidney Disease
• Type 2 Diabetes-Associated Kidney Disease

Global Diabetic Kidney Disease Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Intravenous

Global Diabetic Kidney Disease Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Diabetic Kidney Disease Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Kidney Clinics
• Ambulatory Care Centers
• Home Care Settings

Global Diabetic Kidney Disease Market Size & CAGR (2026-2033)

• North America (Drug Class, Disease Stage, Diabetes Type, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Drug Class, Disease Stage, Diabetes Type, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Disease Stage, Diabetes Type, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Disease Stage, Diabetes Type, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Disease Stage, Diabetes Type, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Innovative Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TheracosBio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lexicon Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daewoong Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GC Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taisho Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations